The Bayer AG logo at the headquarters in France.  Photo: Reuters/Benoit Tessier/File

Bayer slashes outlook as glyphosate demand weakens further

Analysts say dry weather conditions hurt farmers' demand for seeds and pesticides

Reuters – Further deterioration in demand for glyphosate-based weed killers led Bayer BAYGn.DE to cut its full-year earnings outlook and announce a 2.5 billion euro ($2.8 billion USD) write-down on glyphosate-related assets. In an unscheduled statement late on Monday, the German drugs and pesticides maker said it was projecting 2023 earnings before interest, taxes, depreciation […] Read more

(Bayer.com)

Bayer under investor pressure to speed up CEO changeover

Drug and chem firm's stock in 'crisis of trust,' investor says

Frankfurt | Reuters — A top-10 shareholder in Bayer on Tuesday called on the group’s supervisory board to replace CEO Werner Baumann quickly, adding to investor pressure to restore trust and revive the German drugmaker’s sagging share price. Despite recent improvements in the company’s agriculture business and drug development prospects, Bayer shares have been weighed […] Read more


(Bayer.com)

Bayer’s agriculture unit, consumer health drive outlook hike

Frankfurt | Reuters – Agriculture and pharmaceuticals company Bayer BAYGn.DE on Thursday lifted its 2022 earnings guidance on strong demand from farmers for its seeds and crop chemicals and higher sales of consumer health products. Bayer is now targeting earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, of about 13 billion […] Read more